Business
NurExone Biologic Inc. Announces First Quarter 2025 Financial Results and Provides Corporate Update
TORONTO and HAIFA, Israel, May 27, 2025 (GLOBE NEWSWIRE) -- NurExone Biologic Inc. (TSXV: NRX...
About this update from Nurexone Biologic Inc
[{"type":"text","content":"NurExone Biologic Inc. Announces First Quarter 2025 Financial Results and Provides Corporate Update\n\n\n\n TORONTO and HAIFA, Israel, May 27, 2025 (GLOBE NEWSWIRE) --\n \n NurExone Biologic Inc.\n \n (TSXV: NRX) (OTCQB: NRXBF) (FSE: J90) (“\n \n NurExone\n \n ” or the “\n \n Company\n \n ”), a preclinical-stage biotechnology company pioneering exosome-based therapies for central nervous system injuries, is pleased to announce its financial results for the first quarter ended March 31, 2025, and provides a corporate update on its recent activities and upcoming milestones.\n \n\n The Company’s full set of unaudited condensed interim consolidated financial statements for the three months ended March 31, 2025, and accompanying management's discussion and analysis can be accessed by visiting the Company's website at\n \n www.nurexone.com\n \n and its SEDAR+ profile at\n \n www.sedarplus.ca\n \n .\n \n\n\n Key Business Highlights\n \n\n\n\n\n Inclusion in the 2025 TSX Venture 50™ list of top-performing companies on the exchange\n \n\n On February 19, 2025, NurExone announced its inclusion in the 2025 TSX Venture 50™, a prestigious annual ranking of the top-performing companies on the TSX Venture Exchange (“\n \n TSXV\n \n ”). NurExone is the only biotech company, and one of two life sciences companies, to receive this designation, highlighting NurExone’s leadership in the emerging field of exosome-based therapies and regenerative medicine for central nervous system injuries. This recognition also highlights NurExone’s strong market performance and strategic advances in the past year, including\n \n 110% share price appreciation and a 209% increase in market cap\n \n .\n \n\n\n\n\n\n Formation of U.S. Subsidiary, Exo-Top Inc.\n \n\n On February 4, 2025, NurExone established Exo-Top Inc. (“\n \n Exo-Top\n \n ”), a wholly owned U.S.-based subsidiary focused on the production and commercialization of exosomes. Exo-Top will operate independently, free from external licensing or royalty obligations, providing strategic flexibility and cost efficiency as NurExone advances its therapeutic pipeline and establishes new commercial collaborations. In April 2025, biotech industry veteran, Mr. Jacob Licht, was appointed Chief Executive Officer of Exo-Top.\n ...